![]() |
市场调查报告书
商品编码
1692342
BCG 疫苗市场 - 全球产业规模、份额、趋势、机会和预测,按产品、应用、配销通路、地区和竞争细分,2020-2030 年BCG Vaccines Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Distribution Channel, By Region & Competition, 2020-2030F |
2024 年全球 BCG 疫苗市场价值为 1.4556 亿美元,预计在预测期内将实现令人印象深刻的成长,到 2030 年的复合年增长率为 5.90%。全球 BCG(卡介苗)疫苗市场在公共卫生领域发挥着至关重要的作用,主要是作为预防结核病 (TB) 的第一线防线。卡介苗历史悠久、用途广泛,至今仍是全球对抗结核病的重要工具。从历史上看,卡介苗是在 20 世纪初开发的,是第一个成功的抗结核病疫苗。自那时起,全球已有数百万人接种了该疫苗,成为史上使用最广泛的疫苗之一。结核病是一种主要影响肺部的传染性细菌感染,它继续对全球健康构成重大挑战,特别是在医疗资源有限的地区。
市场概况 | |
---|---|
预测期 | 2026-2030 |
2024 年市场规模 | 1.4556亿美元 |
2030 年市场规模 | 2.0365亿美元 |
2025-2030 年复合年增长率 | 5.90% |
成长最快的领域 | 医院 |
最大的市场 | 北美洲 |
全球卡介苗市场的一个主要特征是它被纳入许多国家的免疫计划中。政府主导的措施和要求确保世界相当一部分人口能够接种卡介苗,通常作为婴儿出生时的剂量。早期接种疫苗是一项重要的预防措施,可以预防结核病并降低严重疾病的风险,尤其是对儿童而言。除了传统的结核病预防作用外,正在进行的研究和开发工作正在扩大卡介苗的潜在应用。例如,人们正在探索孕产妇免疫接种作为一种保护母亲和婴儿免受结核病以外的各种感染(如呼吸道疾病)影响的方法。
发展中国家和欠发达国家结核病发生率不断上升
供应链中断
新出现的结核病菌株
Global BCG Vaccines Market was valued at USD 145.56 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.90% through 2030. The global BCG (Bacillus Calmette-Guerin) vaccine market plays a crucial role in the realm of public health, primarily as a frontline defense against tuberculosis (TB). With its rich history and widespread usage, the BCG vaccine remains a vital tool in the global fight against TB. Historically, the BCG vaccine was developed in the early 20th century as the first successful vaccine against TB. Since then, it has been administered to millions of individuals worldwide, making it one of the most widely used vaccines in history. TB, a contagious bacterial infection that primarily affects the lungs, continues to pose a significant global health challenge, particularly in regions with limited access to healthcare resources.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 145.56 Million |
Market Size 2030 | USD 203.65 Million |
CAGR 2025-2030 | 5.90% |
Fastest Growing Segment | Hospitals |
Largest Market | North America |
One of the key features of the global BCG vaccine market is its inclusion in the immunization programs of many countries. Government-led initiatives and mandates ensure that a substantial portion of the world's population receives the BCG vaccine, often as a birth dose to infants. This early vaccination serves as a crucial preventive measure, offering protection against TB and reducing the risk of severe forms of the disease, particularly in children. In addition to its traditional role in TB prevention, ongoing research and development efforts are expanding the potential applications of the BCG vaccine. Maternal immunization, for example, is being explored as a means to provide both mothers and infants with protection against various infections beyond TB, such as respiratory illnesses.
Key Market Drivers
Increasing Prevalence of Tuberculosis in Developing and under-developed countries
The increasing prevalence of tuberculosis (TB) in developing and underdeveloped countries is a significant driver for the growth of the Bacillus Calmette-Guerin (BCG) vaccine market. For instance, in February 2022, the Ministry of Health and Family Welfare, Government of India, published the "India TB Report 2022." The report highlighted that pediatric tuberculosis remains a significant concern, contributing to approximately 31% of the global TB burden. As a result, the increasing BCG vaccination rate among children is expected to drive higher immunization coverage within the target population. This growing emphasis on BCG vaccination for pediatric TB prevention is anticipated to boost market expansion, supporting efforts to combat tuberculosis more effectively. BCG is a widely used vaccine for the prevention of tuberculosis, and its demand is directly linked to the TB burden in these regions. Here's how the rising TB prevalence contributes to the expansion of the BCG vaccine market: Developing and underdeveloped countries often face higher TB incidence rates due to various factors such as overcrowding, limited access to healthcare, and weakened immune systems among their populations. TB remains a critical public health issue in these regions, making vaccination a crucial strategy for prevention.
Key Market Challenges
Supply chain disruptions
Supply chain disruptions have emerged as a significant challenge for the BCG (Bacillus Calmette-Guerin) vaccine market, impacting the production, distribution, and availability of this critical immunization tool. These disruptions, often stemming from various global factors, have far-reaching consequences for the global efforts to combat tuberculosis (TB) through BCG vaccination. The manufacturing of vaccines like BCG requires a complex supply chain, including the procurement of specific raw materials. Disruptions in the availability of these materials, often due to factors like trade restrictions, natural disasters, or geopolitical tensions, can hinder vaccine production.
The BCG vaccine is produced in select facilities and then distributed globally. Interruptions in transportation networks, such as those caused by the COVID-19 pandemic, can lead to delays in the delivery of vaccines to their intended destinations. These delays can impact vaccination programs and contribute to vaccine shortages. BCG vaccines, like many other vaccines, require strict temperature control throughout the supply chain to maintain their efficacy. Any interruptions or failures in the cold chain, whether due to equipment malfunctions or logistical challenges, can render vaccines ineffective and result in wastage. Ensuring an adequate supply of BCG vaccines relies on the capacity of manufacturing facilities. Disruptions caused by issues such as equipment breakdowns or regulatory obstacles can limit the production volume, leading to supply shortages. Political tensions and trade disputes can affect the movement of vaccines and their components across borders. Export restrictions and tariffs can disrupt the flow of vaccines, exacerbating supply chain challenges.
Key Market Trends
Emerging TB strains
Emerging strains of tuberculosis (TB) have become a concerning trend in recent years, posing a significant challenge to TB control efforts and the Bacillus Calmette-Guerin (BCG) vaccine market. Several factors contribute to the emergence of new TB strains, which are increasingly drug-resistant and harder to treat: The overuse and misuse of antibiotics have led to the development of drug-resistant TB strains. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are particularly worrisome. These strains do not respond to first-line TB drugs, making treatment more complex, lengthy, and expensive.
In an interconnected world with increased global travel and population mobility, TB strains can easily cross borders. Infected individuals may carry drug-resistant TB strains with them, introducing these strains to new regions and populations. Immune-compromised individuals, such as those living with HIV/AIDS, are more susceptible to TB and its drug-resistant forms. This population provides fertile ground for the emergence and spread of TB strains that are more resistant to treatment. Weakened TB control programs in some regions may contribute to the persistence and spread of TB. Inadequate diagnosis, treatment, and infection control measures can allow drug-resistant strains to flourish. TB is a genetically diverse bacterium, and its strains can vary in virulence and resistance. The BCG vaccine, derived from a specific strain, may offer limited protection against some of these diverse TB strains. Advancements in genomics and molecular epidemiology have improved our ability to track and analyze TB strains. Researchers can now identify and characterize emerging strains more effectively, enabling targeted responses and treatment strategies.
In this report, the Global BCG Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the BCG Vaccines Market.
Global BCG Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: